PINK:CSLLY
CSL Ltd. Stock News
$92.36
+0.630 (+0.687%)
At Close: May 07, 2024
CSL Ltd (CSLLY) Q2 2024 Earnings Call Transcript
12:53am, Tuesday, 13'th Feb 2024
CSL Ltd (CSLLY) Q2 2024 Earnings Call Transcript
CSL Limited (CSLLY) Q4 2023 Earnings Call Transcript
02:37am, Tuesday, 15'th Aug 2023
CSL Limited (OTCQX:CSLLY) Q4 2023 Earnings Conference Call August 14, 2023 9:00 PM ET Company Participants Mark Dehring - Head of Investor Relations Paul McKenzie - Chief Executive Officer Joy Linton
Biotech firm CSL's full-year profit rises on higher plasma collections
07:00pm, Monday, 14'th Aug 2023
Australia's CSL reported an annual profit on Tuesday that rose 8% as higher plasma collections helped the biotech company counter the impact of currency fluctuations and higher costs.
New Strong Sell Stocks for August 14th
08:39am, Monday, 14'th Aug 2023
AGO, BATL and CSLLY have been added to the Zacks Rank #5 (Strong Sell) List on August 14, 2023.
5 Diverse Medical Stocks to Buy for 2023 and Beyond
07:01pm, Thursday, 06'th Apr 2023
The top and bottom-line growth make these Zacks Medical stocks very attractive.
CSL Limited (CSLLY) Q2 2023 Earnings Call Transcript
03:13am, Tuesday, 14'th Feb 2023
CSL Limited (OTCPK:CSLLY) Q2 2023 Earnings Conference Call February 13, 2023 7:00 PM ET Company Participants Mark Dehring - Head, Investor Relations Paul Perreault - Chief Executive Officer Joy Linton
What Makes CSL Limited Sponsored ADR (CSLLY) a Good Fit for 'Trend Investing'
10:33am, Wednesday, 18'th Jan 2023
CSL Limited Sponsored ADR (CSLLY) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that m
Ranking The 10 Largest Biotechs By Pipeline
12:34pm, Wednesday, 11'th Jan 2023
The pipeline is the heart of all drug discovery companies, leading to all growth in the future. As such, understanding the relative strength of a pipeline by comparing to peers can lead to investment
100 Best Stocks Of 2022: Oil Stocks And Medicals Shine
06:00pm, Friday, 30'th Dec 2022
Medical and energy companies, including oil stocks, lead the list of the 100 best stocks in 2022. The post 100 Best Stocks Of 2022: Oil Stocks And Medicals Shine appeared first on Investor's Business
CSL Limited: R&D Efforts And M&A Deal In The Limelight
10:11am, Tuesday, 15'th Nov 2022
CSL Limited's recent R&D investor briefing suggests that the company has been able to build a strong R&D pipeline without overspending. Separately, CSL Limited expects the top line of its recently acq
CSL Limited (CSLLY) CEO Paul Perreault on Q4 2022 Results - Earnings Call Transcript
03:11am, Wednesday, 17'th Aug 2022
CSL Limited (OTCPK:CSLLY) Q4 2022 Earnings Conference Call August 16, 2022 9:00 PM ET Company Participants Mark Dehring - Head, Investor Relations Paul Perreault - Chief Executive Officer Joy Linton -
Sleeping Aids Market Size Is Projected to Reach $118.31 Billion by 2030 | CAGR: 7.1% : Polaris Market Research
02:02pm, Monday, 14'th Mar 2022 Benzinga
NEW YORK , March 14, 2022 /PRNewswire/ -- Polaris Market Research recently published a research report on "Sleeping Aids Market Share, Size, Trends, Industry Analysis Report, By Product (Mattresses & Pillows, Sleep Laboratories, Medications, Sleep Apnea Devices); By Sleep Disorders; By Region; Segment Forecast, 2022 - 2030" in its research database. According to research report published by Polaris Market Research, the global Sleeping Aids Market size expected to reach to USD 118.31 Billion by 2030 from USD 64.08 Billion in 2021, at a compound annual growth rate (CAGR) of 7.1% during forecast period 2022 to 2030. Report Overview: Sleeping aids products are used in the form of medicines and medical devices to ensure proper monitoring, diagnosis, and treatment for sleep disturbances and disorders. Symptoms of sleep disorders include excessive daytime sleepiness, irregular breathing, or increased movement during sleep. Sleep disorders causes problems with the quality, timing, and amount of sleep, which result in irregular breathing and abnormal sleeping behaviors.
Why CSL (ASX: CSL) shares climbed on Monday
05:41am, Monday, 14'th Mar 2022 The Motley Fool Australia
The biotech giant had a good start to the trading week today. The post Why CSL (ASX: CSL) shares climbed on Monday appeared first on The Motley Fool Australia .
Vaccines Global Market Report 2022
07:59am, Friday, 04'th Mar 2022 GlobeNewswire
Major players in the vaccine market are AstraZeneca, Emergent Biosolutions, Glaxosmithkline, Merck, Pfizer, Sanofi Pasteur, Abbott, Astellas Pharma, Bavarian Nordic, CSL Limited, Daiichi Sankyo Company, Johnson & Johnson, Mitsubishi Tanabe Pharma Corporation, Serum Institute of India, Takeda Pharmaceutical Co. Major players in the vaccine market are AstraZeneca, Emergent Biosolutions, Glaxosmithkline, Merck, Pfizer, Sanofi Pasteur, Abbott, Astellas Pharma, Bavarian Nordic, CSL Limited, Daiichi Sankyo Company, Johnson & Johnson, Mitsubishi Tanabe Pharma Corporation, Serum Institute of India, Takeda Pharmaceutical Co.
Seqirus and U.S. Government Renew Multi-Year Agreement for Influenza Pandemic Preparedness and Response
01:30pm, Friday, 25'th Feb 2022 Benzinga
SUMMIT, N.J. , Feb. 25, 2022 /PRNewswire/ -- Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX:CSL), today announced the renewal of a five-year agreement with the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). 1 The agreement further strengthens the U.S. government''s pandemic preparedness and response capability by ensuring ready production of medical countermeasures (MCMs). This allows BARDA to request that Seqirus provide influenza vaccines and adjuvants for pre-pandemic stockpiling or for manufacture to support rapid response to an influenza pandemic or other public health emergency. Seqirus and BARDA have held similar agreements since 2006. Seqirus stands ready to provide BARDA with: Supply of AUDENZ™ (Influenza A(H5N1) Monovalent Vaccine, Adjuvanted), the first-ever adjuvanted, cell-based influenza vaccine designed to help protect individuals six months of age and older against influenza A(H5N1) in the event of a pandemic. 2 The vaccine combines Seqirus'' proprietary MF59 ® adjuvant technology with its cell-based manufacturing platform.